• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.

作者信息

Kitano Goshi, Kojima Takahiro

机构信息

Department of Urology, Aichi Cancer Center Hospital, Nagoya, Japan.

出版信息

Transl Androl Urol. 2024 Aug 31;13(8):1336-1340. doi: 10.21037/tau-24-172. Epub 2024 Aug 12.

DOI:10.21037/tau-24-172
PMID:39280655
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11399020/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcdd/11399020/b6d61edc26fc/tau-13-08-1336-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcdd/11399020/b6d61edc26fc/tau-13-08-1336-f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcdd/11399020/b6d61edc26fc/tau-13-08-1336-f1.jpg

相似文献

1
Optimal choice of first-line treatment for advanced renal cell carcinoma based on the results of extended follow-up data.基于长期随访数据结果的晚期肾细胞癌一线治疗的最佳选择
Transl Androl Urol. 2024 Aug 31;13(8):1336-1340. doi: 10.21037/tau-24-172. Epub 2024 Aug 12.
2
Prognostic impact of complete metastasectomy in metastatic renal cell carcinoma in the era of immuno-oncology-based combination therapies.免疫肿瘤学联合治疗时代转移性肾细胞癌完全转移灶切除术的预后影响。
World J Urol. 2022 May;40(5):1175-1183. doi: 10.1007/s00345-022-03960-1. Epub 2022 Feb 26.
3
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?免疫肿瘤联合治疗中晚期或中高危国际转移性肾细胞癌数据库联盟标准治疗的晚期肾细胞癌患者的真实世界结局：风险组的疗效差异？
Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
4
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.全球免疫肿瘤联合治疗晚期肾细胞癌患者的真实世界结局：ARON-1 研究。
Target Oncol. 2023 Jul;18(4):559-570. doi: 10.1007/s11523-023-00978-2. Epub 2023 Jun 27.
5
Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma.转移性透明细胞肾细胞癌的一线治疗方法
Curr Oncol Rep. 2022 Jun;24(6):695-702. doi: 10.1007/s11912-022-01196-1. Epub 2022 Mar 5.
6
Real world data on IO-based therapy for metastatic renal cell carcinoma.基于真实世界数据的转移性肾细胞癌的 IO 治疗。
J Cancer Res Clin Oncol. 2023 Jul;149(7):3249-3258. doi: 10.1007/s00432-022-04173-0. Epub 2022 Jul 30.
7
Efficacy and Safety of Immuno-Oncology Plus Tyrosine Kinase Inhibitors as Late-Line Combination Therapy for Patients with Advanced Renal Cell Carcinoma.免疫肿瘤学联合酪氨酸激酶抑制剂作为晚期肾细胞癌患者后线联合治疗的疗效与安全性
J Clin Med. 2024 Jun 7;13(12):3365. doi: 10.3390/jcm13123365.
8
A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.美国食品和药物管理局对转移性肾细胞癌不同风险组一线联合治疗生存获益的汇总分析。
Eur Urol. 2023 Oct;84(4):373-378. doi: 10.1016/j.eururo.2023.05.030. Epub 2023 Jun 2.
9
Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era.晚期非透明细胞肾细胞癌患者从酪氨酸激酶抑制剂时代到免疫肿瘤时代结局的变化。
Int J Clin Oncol. 2024 Nov;29(11):1730-1739. doi: 10.1007/s10147-024-02606-z. Epub 2024 Aug 14.
10
Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations.一线免疫治疗联合治疗后转移性透明细胞肾细胞癌二线治疗的无进展生存期。
Eur Urol. 2023 Mar;83(3):195-199. doi: 10.1016/j.eururo.2022.10.017. Epub 2022 Nov 4.

本文引用的文献

1
Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study.仑伐替尼联合帕博利珠单抗对比舒尼替尼用于晚期肾细胞癌一线治疗：CLEAR 研究的最终预设总生存分析，一项 III 期研究。
J Clin Oncol. 2024 Apr 10;42(11):1222-1228. doi: 10.1200/JCO.23.01569. Epub 2024 Jan 16.
2
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.帕博利珠单抗联合阿昔替尼与舒尼替尼作为晚期肾细胞癌一线治疗的比较：3期KEYNOTE-426研究的43个月随访
Eur Urol. 2023 Nov;84(5):449-454. doi: 10.1016/j.eururo.2023.06.006. Epub 2023 Jul 25.
3
Erratum: Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial.
勘误：纳武利尤单抗联合卡博替尼与舒尼替尼用于晚期肾细胞癌（aRCC）一线治疗的3年随访：3期CheckMate 9 ER试验结果
J Clin Oncol. 2023 Jul 20;41(21):3767. doi: 10.1200/JCO.23.00901. Epub 2023 May 9.
4
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study.乐伐替尼联合帕博利珠单抗对比舒尼替尼作为晚期肾细胞癌患者一线治疗（CLEAR）：3期随机开放标签研究的延长随访
Lancet Oncol. 2023 Mar;24(3):228-238. doi: 10.1016/S1470-2045(23)00049-9.
5
Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma.纳武利尤单抗联合伊匹单抗对比舒尼替尼治疗晚期肾细胞癌患者的条件生存和长期疗效。
Cancer. 2022 Jun 1;128(11):2085-2097. doi: 10.1002/cncr.34180. Epub 2022 Apr 5.
6
Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial.一线纳武利尤单抗联合卡博替尼与舒尼替尼治疗晚期肾细胞癌患者的患者报告结局：CheckMate 9ER 开放标签、随机、III 期试验。
Lancet Oncol. 2022 Feb;23(2):292-303. doi: 10.1016/S1470-2045(21)00693-8. Epub 2022 Jan 12.
7
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.纳武利尤单抗联合卡博替尼对比舒尼替尼用于晚期肾细胞癌。
N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982.
8
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.仑伐替尼联合帕博利珠单抗或依维莫司治疗晚期肾细胞癌。
N Engl J Med. 2021 Apr 8;384(14):1289-1300. doi: 10.1056/NEJMoa2035716. Epub 2021 Feb 13.
9
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.派姆单抗联合阿昔替尼对比舒尼替尼作为晚期肾细胞癌的一线治疗（KEYNOTE-426）：一项随机、开放标签、III 期试验的延长随访。
Lancet Oncol. 2020 Dec;21(12):1563-1573. doi: 10.1016/S1470-2045(20)30436-8. Epub 2020 Oct 23.
10
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial.纳武利尤单抗联合伊匹木单抗与舒尼替尼一线治疗晚期肾细胞癌：III期CheckMate 214试验的4年延长随访
ESMO Open. 2020 Nov;5(6):e001079. doi: 10.1136/esmoopen-2020-001079.